Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy

Introduction: The TESTING trial demonstrated that corticosteroids reduce the risk of kidney failure in patients with IgA nephropathy (IgAN) but increase the risk of serious adverse events. Reliable noninvasive biomarkers are needed to identify patients who would benefit most from corticosteroid ther...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jingyi Li, Jicheng Lv, Muh Goet Wong, Sufang Shi, Jincan Zan, Helen Monaghan, Vlado Perkovic, Hong Zhang, Rajiv Agarwal, Sean Barbour, Daniel Cattran, Alan Cass, Tak Mao Chan, John Feehally, Richard Glassock, Michelle A. Hladunewich, Lai Seong Hooi, Meg J. Jardine, Vivekanand Jha, David W. Johnson, Adeera Levin, Zhi-Hong Liu, Heather Reich, Giuseppe Remuzzi, David C. Wheeler, Muh Geot Wong, Mark Woodward, Yangfeng Wu, Minghui Zhao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-10-01
coleção:	Kidney International Reports
Assuntos:	crescentic lesions IgA nephropathy treatment u-sCD163
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2468024924018618
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!